Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland

Abstract The interleukin-6 (IL-6) inhibitors tocilizumab and sarilumab have been repurposed for COVID-19 treatment. However, discrepancies exist across global and national COVID-19 guidelines, with limited data on the comparative effectiveness between these therapeutics especially during the delta/o...

Descripción completa

Detalles Bibliográficos

Autores principales:	Bang Zheng, Amanj Kurdi, Alain Amstutz, Amelia Green, Emily Herrett, John Tazare, Qing Wen, Viyaasan Mahalingasivam, Rebecca Smith, Brian MacKenna, Amir Mehrkar, Seb Bacon, Ben Goldacre, Chris Robertson, Sir Aziz Sheikh, Laurie Tomlinson, On behalf of The OpenSAFELY Collaborative
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2026-05-01
Colección:	Nature Communications
Acceso en línea:	https://doi.org/10.1038/s41467-026-73134-9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!